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Background: Lipoprotein(a) [Lp(a)] has enhanced atherothrombotic properties. Also,
Lp(a) is known to be associated with cardiovascular complications of general
populations. However, the ability of Lp(a) levels to predict adverse cardiovascular
outcomes in patients (pts) undergoing percutaneous coronary intervention (PCI) with
drug-eluting stents (DESs) has not been examined.
Methods: The study population consisted of 1015 consecutive pts underwent PCI with
DESs enrolled from 2004 to 2008. We subdivided the pts into 2 groups of plasma Lp(a)
concentration: Lp(a) <50 (n=1215), and Lp(a)≥50 mg/dl (n=241). 2-year cumulative
major clinical outcomes were compared among two groups.
Results: The baseline clinical characteristics including age, diabetes, hypertension,
smoking, chronic kidney disease, left ventricular ejection fraction, myocardial
infarction, number of coronary vessel disease were similar among two groups except
gender, dyslipidemia, hemoglobin, and serum creatinine level (table). At 2-year follow-
up (82.6%), major clinical outcomes including total major adverse cardiac events
(MACE), target vessel revascularization (TLR), target lesion revascularization (TVR),
TLR-MACE, TVR-MACE, and all death were higher in Lp(a)≥50 mg/dl group (table).
Also, Multivariate analysis adjusted by gender, dyslipidemia, Hemoglobin, and
creatinine showed that total MACE, TLR-MACE, TVR-MACE, TLR, and TVR were
significantly higher in Lp(a)≥50 mg/dl group (table).
Conclusion: In our study, Lp(a) level in pts undergoing PCI with DESs was closely
associated with worse clinical outcomes up to 2 years.
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Background: ApoB/ApoA-I ratio is known to be associated with cardiovascular
complications of general populations. However, there have been limited data whether
the association of Apo B/Apo A-I ratio and clinical outcomes of patients (pts)
undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DESs).
Methods: The study population consisted of 415 consecutive pts underwent PCI with
DESs enrolled from 2004 to 2008. 2-year cumulative major clinical outcomes of pts
with high ApoB/ApoA-I ratio group (≥0.8, n= 102) was compared with those of low
ApoB/ApoA-I ratio group (<0.8, n=313).
Results: The baseline clinical characteristics including gender, age, diabetes,
hyperlipidemia, chronic kidney disease, smoking were similar between the two groups
except acute myocardial infarction (AMI), hypertension (HTN), total cholesterol,
triglyceride, LDL cholesterol, HDL cholesterol, Lipoprotein(a) [Lp(a)] level (table).
2-year major clinical outcomes were not different between the two groups except total
MACE (Table). When adjusted by AMI, HTN, total MACE was a trend to increase in
high ApoB/ApoA-I ratio group than low high ApoB/ApoA-I ratio group (p= 0.099).
Conclusion: In our study, high level of ApoB/ApoA-I ratio in pts undergoing PCI with
DESs may be associated with total MACE up to 2 year follow-up, as compared to those
of control group.
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Background: Coronary artery tortuosity poses a challenge to the interventionalist. The
Terumo Heartrail Catheter is a mother and child system that allows for deep intubation
of the vessel to facilitate balloon and stent delivery. We describe our experience with
this device for safety and efficacy in planned and bailout procedures.
Methods: We identified cases necessitating the use of the Heartrail catheter either as
planned or as bailout strategy from August 2008. Demographic, procedural and
outcome data were collected prospectively.
Results: A total of 29 patients (75.9% male) were enrolled. Mean age was 69.8(+/-
9.69). Mean LV ejection fraction was 47.05% (+/-8.26). 6 patients presented as ST
elevation MI, 5 requiring primary PCI. 20% of all cases were done via radial approach,
66.7% involved the RCA, 75% were type C lesions and 2 cases involved chronic total
occlusions. Severe calcification was seen in 45.8% of cases. Successful stent
deployment occurred in 24/29cases. Vessel characteristics that may predict failure for
stent delivery using conventional techniques include severe proximal calcification
(10/24), vessel tortuosity (>2 bends at 45%, 8/24) and distal vessel dissection after
predilation (5/24). The mean intubation depth for Heartrail catheter was 4.81+/- 2.35cm
with depths >3cm ensuring success in 18/21cases. The 3 failed cases all involved the.
There were no major complications associated with this device and 100% survival was
seen at 30days.
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